Chengdu HuaRenKang Biotechnology
Chengdu HuaRenKang Biotechnology is a wholly-owned subsidiary of Chengdu Maxvax Biotechnology and was established in 2020 with a registered capital of RMB 200 million. It has a nearly 7,000-square-meter human vaccine R&D center and pilot plant at Chengdu Tianfu International Bio-Town, which includes three different types of adjuvant workshops and two pilot-scale drug filling production lines. It is capable of producing Phase I/II clinical trial samples for recombinant engineered bacterial and cellular protein vaccines, as well as live attenuated vaccines.
Chengdu Tianfu International Biological City (Building 2, No. 8, Huigu East 1st Road, Shuangliu District)
(+86) 028-85329858
